友邦保險(01299.HK)根據代理購股計劃發行111.98萬股
格隆匯4月29日丨友邦保險(01299.HK)公佈,茲提述公司於2012年2月23日採納的代理購股計劃("代理購股計劃")。
公司董事會宣佈根據代理購股計劃,公司將向香港中央證券信託有限公司發行111.9763萬股股份("獲授股份"),其將以信託方式為參與代理購股計劃的若干合資格代理("獲授代理")持有獲授股份。獲授股份的歸屬條件於2022年4月29日已獲符合,而發行獲授股份僅須待聯交所批准獲授股份的上市及買賣。
將予發行的獲授股份佔(i)於公吿日期的已發行股份約0.01%;及(ii)根據經發行及配發獲授股份擴大後的已發行股本約0.01%。
公司擬將發行獲授股份的所得款項淨額用於為代理購股計劃的行政開支提供資金以及用作公司一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.